Diaceutics PLC Diaceutics launches daily alerts for DXRX platform
29 Agosto 2023 - 8:00AM
RNS Non-Regulatory
TIDMDXRX
Diaceutics PLC
29 August 2023
RNS Reach
29 August 2023
Diaceutics launches daily alerts for DXRX platform
Daily alerts will enable pharma clients to identify patients
previously not receiving the most appropriate treatment due to lack
of timely data
Diaceutics PLC (AIM: DXRX), a leading technology and solutions
provider to the pharmaceutical industry , is pleased to announce an
important and innovative upgrade to its DXRX platform which sees
the Company's DXRX Signal product now providing alerts on a daily
basis. This ground-breaking innovation will provide Diaceutics'
customers with even more timely data to identify patients who would
benefit from their therapies and improve their commercial success.
For patients, it means their chances of receiving the optimal
therapy within the window of effectiveness is significantly
improved.
DXRX Signal utilizes real-world data collected from a diverse
network of over 500 labs, encompassing academic, community, and
commercial facilities. This comprehensive data pool ensures supply
chain reliability and encompasses both geographical and clinical
diversity. For Diaceutics' customers, this translates into
extensive coverage across a spectrum of medical conditions,
including oncology, rare diseases, auto-immune disorders,
cardiovascular and infectious diseases.
DXRX Signal has identified over 46,000 patients so far in 2023
for its biopharma clients.
Building upon the foundation of DXRX Signal, Diaceutics has
introduced this pivotal enhancement. These alerts, now available on
a daily basis, empower Diaceutics' customers with even timelier
insights as they deploy products to pinpoint patients and elevate
their commercial success. This innovation equips healthcare
professionals with crucial data on a daily basis, and within days
of a positive test result. With increased timely access to
diagnostic information, physicians can be engaged precisely during
the treatment decision window, ensuring the most effective drugs or
therapies are offered promptly to patients.
In 2022, the 'Practice Gaps Study' highlighted the existence of
seven distinct clinical practice gaps. These gaps collectively
contributed to a concerning statistic: 64.4% of cancer patients did
not receive the appropriate targeted therapy, of which, 29.2% of
patients were lost at the critical treatment decision juncture of
their medical journey. DXRX Signal specifically targets this cohort
of patients, previously not receiving the most appropriate
treatment due to lack of timely data .
Available only through the Diaceutics platform, DXRX Signal
utilizes our lab data to identify physicians with a patient who has
tested positive for a specific biomarker of interest, which may be
eligible for therapy. This signal is seamlessly integrated within a
customers' operations within as little as 48 hours of the positive
test result. From this, they are able to target that physician with
a well-informed engagement before a treatment decision has been
made so that they can offer a more effective drug or therapy
sooner; a key goal for all involved in precision medicine.
Jordan Clark, Chief Commercial Officer of Diaceutics plc,
commented: "We recognize the critical importance of engaging
physicians during the treatment decision window. By utilizing DXRX
Signal, we empower our clients to capitalise on this pivotal
moment, ultimately reducing patient losses during this vital stage
- the largest 'practice gap.' This enhancement not only increases
awareness and biomarker-precision medicine association but also
ensures patients receive the precise treatments they deserve,
fostering superior clinical outcomes."
Peter Keeling, Chief Executive Officer of Diaceutics plc,
commented: "We are breaking new ground with DXRX Signal. This data
has simply not been accessible previously to pharma, which we
believe is one of the reasons such a worryingly high proportion of
patients who could benefit from precision medicine are not
receiving it in time. In 2023, we have so far identified over
46,000 patients for whom a specific medicine could change their
clinical outcome and we will continue to innovate to ensure that
that number increases minute by minute, hour by hour."
Enquiries:
Diaceutics PLC Tel: +44 (0)28 9040 6500
Peter Keeling, Chief Executive Officer investorrelations@diaceutics.com
Ryan Keeling, Chief Innovation Officer
Nick Roberts, Chief Financial Officer
Stifel Nicolaus Europe Limited (Nomad Tel: +44 (0)20 7710 7600
& Broker)
Ben Maddison
Nick Harland
Kate Hanshaw
Alma PR Tel: +44 (0)20 3405 0205
Caroline Forde diaceutics@almapr.co.uk
Matthew Young
Kinvara Verdon
About Diaceutics
At Diaceutics we believe that every patient should get the
opportunity to receive the right test and the right therapy to
positively impact their disease outcome. We provide the world's
leading pharmaceutical and life science companies with solutions
and technology for the commercialisation of their precision
medicines, enabled by our proprietary DXRX platform.
DXRX is the world's first diagnostic commercialisation platform
for precision medicine, utilising a global network of affiliate
laboratories to deliver multiple pipelines of real-world healthcare
data insights, advisory services and innovative platform enabled
solutions.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAFLFLVTTIDFIV
(END) Dow Jones Newswires
August 29, 2023 02:00 ET (06:00 GMT)
Grafico Azioni Diaceutics (LSE:DXRX)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Diaceutics (LSE:DXRX)
Storico
Da Mag 2023 a Mag 2024